The Worldwide Brain Tumor Therapeutics Industry is Expected to Reach $4.7 Billion by 2026 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Brain Tumor Therapeutics" report has been added to ResearchAndMarkets.com's offering.

The Global Brain Tumor Therapeutics Market is estimated to be USD 2.89 Bn in 2021 and is expected to reach USD 4.70 Bn by 2026, growing at a CAGR of 10.2%.

The rapidly increasing prevalence of neurological disorders are identified in adults and children is augmenting the market growth. Brain disorders, which comprise an amalgamation of psychiatric, developmental, and neurodegenerative diseases, are a rising cause of morbidity globally.

The market's growth is rising incidences of brain cancer and other neurological disorders, rising need for tests detecting the presence of tumors, and research activities in molecular diagnostics. The market may face possible challenges in the growth due to side effects associated with brain tumor therapeutics.

The growing use of targeted therapies will act as a major restraining factor. High costs associated with the diagnosis and treatment may affect the market growth. The market is expected to showcase opportunities such as rising healthcare expenditure and favorable reimbursement policies, growing healthcare awareness about brain tumor management and therapies, and government initiatives for cancer awareness.

The Global Brain Tumor Therapeutics Market is segmented based on Therapy Type, Indication, Distribution Channel, and Geography.

Countries Studied

• America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
• Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
• Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
• Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

• The report offers a comprehensive evaluation of the Global Brain Tumor Therapeutics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
• The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
• The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
• The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
• The report also contains the competitive analysis using IGR Positioning Quadrants, Infogence's Proprietary competitive positioning tool.

Market Dynamics

Drivers

• Rising Incidences of Brain Cancer and Other Neurological Disorders
• Rising Need for Tests Detecting the Presence Of Tumor
• Research Activities in the Molecular Diagnostics

Restraints

• High Cost Associated with the Diagnosis and Treatment

Opportunities

• Rising Healthcare Expenditure & the Favourable Reimbursement Policies
• Growing Healthcare Awareness About the Management and Therapies of Brain Tumor
• Government Initiatives of Cancer Awareness

Challenges

• Side Effects Associated with Brain Tumor Therapeutics

Companies Mentioned

• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol -Myers Squibb Co
• Eisai Inc
• Emcure Pharmaceutics
• F. Hoffmann-La Rosche Ltd.
• Genentech, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co. Inc.
• NextSource
• Novartis AG
• Pfizer Inc.
• Y-mAbs Therapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/r/3uk6s0